UTI Healthcare Fund · Regular · Growth
NAV
₹349.6925
as of 13 Nov 2026
Expense Ratio
2.20%
AUM
₹1,399 Cr
Lumpsum returns (CAGR)
- 1Y
- +20.86%
- 3Y
- +22.69%
- 5Y
- +16.33%
- Since Inception
- +13.25%
SIP returns (XIRR)
- 1Y
- +30.16%
- 3Y
- +18.58%
- 5Y
- +20.96%
- Since Inception
- +15.48%
Returns calculated from 16 September 2014 onwards due to a structural change in the scheme on that date. Earlier NAV history is preserved but excluded from multi-year return calculations. Periods spanning this date show —.
What history actually did — last 10 years (Nov 2016 – Nov 2026)
A ₹5,000 monthly SIP for the last 10 years (Nov 2016 – Nov 2026)
Real NAV backtest
A ₹5,000 monthly SIP would be worth ₹15,86,534 today — ₹6,00,000 invested, 18.7% XIRR.
₹6,00,000
Invested
₹15,86,534
Value today
18.7%
XIRR (p.a.)
A ₹1,00,000 lumpsum, the last 10 years (Nov 2016 – Nov 2026)
Real NAV backtest
₹1,00,000 invested 10 years ago would be ₹3,96,034 today (14.8% CAGR).
A regular withdrawal plan (SWP)
Real NAV backtest
A ₹10,00,000 corpus withdrawing ₹5,000/month since Nov 2016 would still hold ₹23,73,811.
Fund vs Benchmark (TRI)
Same SIP, benchmark total-return index
The same SIP would be worth ₹15,86,534 in this fund vs ₹11,99,859 in the benchmark — outperformance of ₹3,86,675.
Buying the worst day
Real NAV backtest
₹1,00,000 invested on the worst market day of the last 10 years (Nov 2016 – Nov 2026) (22 Mar 2020) would be ₹4,73,879 today (4.74×).
Historical simulation using actual published NAVs for the stated period. Past performance may or may not be sustained in the future. Not investment advice.
Risk Metrics
Trailing 1 year, annualised0.88
Sharpe Ratio
+0.14
Alpha
0.65
Beta
0.87
Sortino
12.48%
Std Dev
-10.39%
Max Drawdown
Performance Comparison
Sectoral allocation
as of 31 Oct 2026- Pharmaceuticals & Biotechnology68.69%
- Healthcare Services25.75%
- Healthcare Equipment & Supplies1.14%
- Chemicals & Petrochemicals0.97%
Each sector links to the mutual funds most exposed to it.
Related reading
Thinking about UTI Healthcare Fund · Regular · Growth?
Talk to our AMFI-registered team — free, no pressure. We'll help you see if this fund fits your goals.
Compare with Similar Funds
Fund Details
Available transactions
Portfolio holdings
- 1Sun Pharmaceuticals Industries7.44%
- 2Divis Laboratories Ltd.6.46%
- 3Dr Reddys Laboratories Ltd.5.78%
- 4Ajanta Pharma Ltd.4.29%
- 5Max Healthcare Institute Ltd4.20%
- 6Gland Pharma Ltd.3.89%
- 7Apollo Hospitals Enterprise Lt3.83%
- 8Alkem Laboratories Ltd3.66%
- 9Lupin Ltd.3.65%
- 10Global Health Ltd.3.37%
What this fund does
UTI Healthcare Fund · Regular · Growth invests in stocks from a specific sector or theme, offering concentrated exposure to a particular area of the economy. These funds carry sector-specific risks but can deliver significant returns when the underlying sector performs well.
About This Fund
UTI Healthcare Fund · Regular · Growth is a Sectoral / Thematic mutual fund offered by UTI Mutual Fund. The fund has been operational for over 27 years. It manages assets worth ₹1,399 Cr, reflecting investor confidence in the fund's strategy. It benchmarks its performance against BSE Healthcare TRI. The current expense ratio is 2.20%.
Who Should Invest?
- •Aggressive investors comfortable with significant short-term volatility
- •Investors with a long-term horizon of 7+ years who can ride out market cycles
- •SIP investors who can benefit from rupee cost averaging during market fluctuations